Eli Lilly to demolish mothballed Erbitux plant in NJ
The former Imclone facility will be knocked down to give Eli Lilly “flexibility for future opportunities” at its Branchburg, New Jersey site, the firm says. Building 36 on Eli Lilly’s Branchburg, New Jersey campus is scheduled to be demolished by the end of the first quarter of 2019, Lilly ...
Novartis says it remains confident Kymriah will pull in $200 million in 2019 through the remediation and ramp-up of its CAR-T manufacturing netwo ...
Roche has expanded its partnership with SQZ Biotechnologies to codevelop therapeutics derived from peripheral blood mononuclear cells (PBMCs) in ...
The construction of a vaccine and biologics production at a site in County Carlow is the latest commitment to Ireland, says Merck & Co.
Me ...
Cell therapy CDMO MaSTherCell will produce late-stage clinical supply of an adoptive cell therapy for Iovance Biotherapeutics from its facility i ...
Recent Tweets
-
RT @MylanNews: Mylan and @Bioconlimited announce positive CHMP Opinion for Ogivri®, biosimilar Trastuzumab https://t.co/AcXjyHmLEB #MYL
4 days ago
-
RT @Dan5tanton: The former 30,000 L single-product Imclone facility will be knocked down to give Eli Lilly $LLY “flexibility for fu… https://t.co/Z5VqxHlU3l
6 days ago
-
In 2013, Danish drugmaker Genmab sold its 22,000 L Minnesota biomanufacturing plant to Baxter for $10m. COO told us… https://t.co/26kUYLoJwG
6 days ago
-
RT @ZacharyBrennan: today is the day... for European Humira biosimilar launches.
Not to worry, just 5 more years until the US launch… https://t.co/Zf5SyyguZz
7 days ago
Trending
Analytical
Trends in Chemistry, Manufacturing, and Controls: Next-Generation Technologies and Product Modalities
Upstream Processing
Cell Culture Media: An Active Pharmaceutical Ingredient or Ancillary Material?
Analytical
Single-Use Sensors and Control and Data Acquisition Tools to Streamline Bioprocess Development
BPI White Papers
Culture of 3D Cell Aggregates in Perfusion in a DASbox® Mini Bioreactor System